WO2024068265A3 - Virus-like particles displaying sars-cov-2 antigens as booster vaccines and uses thereof - Google Patents

Virus-like particles displaying sars-cov-2 antigens as booster vaccines and uses thereof Download PDF

Info

Publication number
WO2024068265A3
WO2024068265A3 PCT/EP2023/075034 EP2023075034W WO2024068265A3 WO 2024068265 A3 WO2024068265 A3 WO 2024068265A3 EP 2023075034 W EP2023075034 W EP 2023075034W WO 2024068265 A3 WO2024068265 A3 WO 2024068265A3
Authority
WO
WIPO (PCT)
Prior art keywords
cov
sars
virus
antigens
particles displaying
Prior art date
Application number
PCT/EP2023/075034
Other languages
French (fr)
Other versions
WO2024068265A2 (en
Inventor
Stephan RAMBICHLER
Maria HINTERBERGER
José MEDINA ECHEVERZ
Jürgen HAUSMANN
Matthias Habjan
Original Assignee
Bavarian Nordic A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic A/S filed Critical Bavarian Nordic A/S
Publication of WO2024068265A2 publication Critical patent/WO2024068265A2/en
Publication of WO2024068265A3 publication Critical patent/WO2024068265A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/625—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier binding through the biotin-streptavidin system or similar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to the use of vaccines comprising virus-like particles displaying at least one SARS-CoV-2 antigen, such as the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, as vaccine boosters. Antigens are displayed on virus-like particles (VLPs) and produce an immune response in vaccinated subjects. The invention also relates to methods of treatment using the recombinant VLPs as boosters to treat and/or prevent infection with SARS-CoV-2, and methods of preparation thereof.
PCT/EP2023/075034 2022-09-30 2023-09-12 Virus-like particles displaying sars-cov-2 antigens as booster vaccines and uses thereof WO2024068265A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP22199004.7 2022-09-30
EP22199004 2022-09-30
EP22205630.1 2022-11-04
EP22205630 2022-11-04

Publications (2)

Publication Number Publication Date
WO2024068265A2 WO2024068265A2 (en) 2024-04-04
WO2024068265A3 true WO2024068265A3 (en) 2024-05-16

Family

ID=88060580

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2023/075034 WO2024068265A2 (en) 2022-09-30 2023-09-12 Virus-like particles displaying sars-cov-2 antigens as booster vaccines and uses thereof

Country Status (1)

Country Link
WO (1) WO2024068265A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021250219A1 (en) * 2020-06-10 2021-12-16 Bavarian Nordic A/S A recombinant modified vaccinia virus ankara (mva) vaccine against coronavirus disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1532167B1 (en) 2002-07-17 2012-01-25 Cytos Biotechnology AG Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
EP3244915A1 (en) 2015-01-15 2017-11-22 University of Copenhagen Virus-like particle with efficient epitope display
AU2021268757A1 (en) 2020-05-07 2022-12-08 Adaptvac Aps Peptide tags and binding partners
WO2022229817A1 (en) 2021-04-28 2022-11-03 Bavarian Nordic A/S Vaccines comprising virus-like particles displaying sars-cov-2 antigens and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021250219A1 (en) * 2020-06-10 2021-12-16 Bavarian Nordic A/S A recombinant modified vaccinia virus ankara (mva) vaccine against coronavirus disease

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FOUGEROUX CYRIELLE ET AL: "Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity", NATURE COMMUNICATIONS, vol. 12, no. 1, 12 January 2021 (2021-01-12), XP055938298, Retrieved from the Internet <URL:http://www.nature.com/articles/s41467-020-20251-8> DOI: 10.1038/s41467-020-20251-8 *
GALE EMILY C. ET AL: "Hydrogel-Based Slow Release of a Receptor-Binding Domain Subunit Vaccine Elicits Neutralizing Antibody Responses Against SARS-CoV-2", ADVANCED MATERIALS, vol. 33, no. 51, 14 October 2021 (2021-10-14), DE, pages 2104362, XP093062525, ISSN: 0935-9648, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1002/adma.202104362> DOI: 10.1002/adma.202104362 *
KATRIN REITER ET AL: "Separation of virus-like particles and extracellular vesicles by flow-through and heparin affinity chromatography", JOURNAL OF CHROMATOGRAPHY A, vol. 1588, 1 March 2019 (2019-03-01), AMSTERDAM, NL, pages 77 - 84, XP055703574, ISSN: 0021-9673, DOI: 10.1016/j.chroma.2018.12.035 *
ZHANG YAO ET AL: "In vitro preparation of uniform and nucleic acid free hepatitis B core particles through an optimized disassembly-purification-reassembly process", PROTEIN EXPRESSION AND PURIFICATION, vol. 178, 1 February 2021 (2021-02-01), SAN DIEGO, CA., pages 105747, XP093062425, ISSN: 1046-5928, DOI: 10.1016/j.pep.2020.105747 *

Also Published As

Publication number Publication date
WO2024068265A2 (en) 2024-04-04

Similar Documents

Publication Publication Date Title
US20240307518A1 (en) Subunit vaccine delivery platform for robust humoral and cellular immune responses
Carroll et al. The vaccine adjuvant chitosan promotes cellular immunity via DNA sensor cGAS-STING-dependent induction of type I interferons
Garçon et al. Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion
Riese et al. Vaccine adjuvants: key tools for innovative vaccine design
Mount et al. Combination of adjuvants: the future of vaccine design
Littauer et al. Stable incorporation of GM-CSF into dissolvable microneedle patch improves skin vaccination against influenza
TW200722101A (en) Novel composition
CN108743937B (en) Vaccine compositions and methods
ZA202210992B (en) Antigen specific immunotherapy for covid-19 fusion proteins and methods of use
Virginio et al. Assessment of the adjuvant activity of mesoporous silica nanoparticles in recombinant Mycoplasma hyopneumoniae antigen vaccines
WO2007008918A3 (en) Virus vaccines comprising envelope-bound immunomodulatory proteins and methods of use thereof
Decker et al. Cytokine adjuvants for vaccine therapy of neoplastic and infectious disease
Okamoto et al. Poly-γ-glutamic acid nanoparticles and aluminum adjuvant used as an adjuvant with a single dose of Japanese encephalitis virus-like particles provide effective protection from Japanese encephalitis virus
WO2021204825A3 (en) INACTIVATED SARS-CoV-2 VIRUS VACCINE
Zhang et al. The effect of aqueous extract of Xinjiang Artemisia rupestris L.(an influenza virus vaccine adjuvant) on enhancing immune responses and reducing antigen dose required for immunity
WO2023094713A3 (en) Coronavirus vaccine
Singh et al. Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein
SA522441314B1 (en) Vaccines for recurrent respiratory papillomatosis and methods of using the same
MX2023012530A (en) Adjuvanted vaccine composition and methods.
WO2003090687A3 (en) Using heat shock proteins to increase immune response
Klatt et al. Effects of persistent modulation of intestinal microbiota on SIV/HIV vaccination in rhesus macaques
Wang et al. Immunization with recombinant Erns-LTB fusion protein elicits protective immune responses against bovine viral diarrhea virus
Yu et al. Combinations of various CpG motifs cloned into plasmid backbone modulate and enhance protective immunity of viral replicon DNA anthrax vaccines
ZA202400113B (en) Adjuvanted inactivated recombinant rabies virus vectored coronavirus vaccine formulations
Shi et al. The expression of membrane protein augments the specific responses induced by SARS-CoV nucleocapsid DNA immunization

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23769188

Country of ref document: EP

Kind code of ref document: A2